SCHEMBL290961

SCHEMBL290961

NCC(F)(F)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15268990 0.97
SCHEMBL2096880 0.83 KDM4E (0.40)
SCHEMBL5704679 0.77
SCHEMBL10411580 0.75
Trifluoroacetic Acid SCHEMBL5567529 0.75 GLRA1 (0.37)
Hydrochloric Acid SCHEMBL18334347 0.75 BLM (0.42)
SCHEMBL14135896 0.73 ALDH1A1 (0.36)
SCHEMBL20664161 0.73
Trifluoroacetic Acid SCHEMBL5564906 0.73 HRH4 (0.35)
Hydrochloric Acid SCHEMBL26618819 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 EP claimed
WO-2022072560-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2022-04-07 WO claimed
WO-2021194908-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2021-09-30 WO claimed
US-20070218371-A1 Nanoporous polymer electrolyte TDA RESEARCH, INC. (US) 2007-09-20 US claimed
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP disclosed
US-12404274-B2 Macrocycles as factor xia inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-02 US disclosed
US-20240027902-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 US disclosed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 EP disclosed
US-11788080-B2 Modified cleavases, uses thereof and related kits Encodia, Inc. (US) 2023-10-17 US disclosed
WO-2007062308-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 WO disclosed
US-20050059611-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-03-17 US disclosed
US-6821960-B2 Glucagon antagonists/inverse agonists NOYO NORDISK PHARMACEUTICALS, INC. 2004-11-23 US disclosed
EP-1345891-A1 GLUCAGON ANTAGONIST/INVERSE AGONIST Novo Nordisk A/S (DK) 2003-09-24 EP disclosed
US-20030027849-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2003-02-06 US disclosed
WO-2002040446-A1 GLUCAGON ANTAGONIST/INVERSE AGONIST NOVO NORDISK A/S (DK) 2002-05-23 WO disclosed
WO-2002040446-A1 GLUCAGON ANTAGONIST/INVERSE AGONIST NOVO NORDISK A/S (DK) 2002-05-23 WO disclosed